Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody

Invivyd

23/12/2025 12:12

** Shares of drugmaker Invivyd IVVD.O  rise 1.4% to $2.92 premarket

** Co says it has started late-stage clinical trial to test its experimental COVID-19 antibody, VYD2311, as a preventive treatment for the disease

** Study will enroll 1,770 adults and teens; compare single vs monthly shots to placebo, says co

** IVVD says the goal is to offer vaccine alternative for high-risk people seeking protection

** Top-line results expected by mid-2026 - IVVD

** Up to last close, stock up ~133% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))